CURX Stock — Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc Common Stock (CURX)

Updated October 16, 2026.

CURX is a Stock. Total return is 14.9% over the past 1.1 years, 5.0 points behind SPY at 19.9%.

Curanex Pharmaceuticals is a developmental stage pharmaceutical company that discovers, develops, and commercializes botanical drugs to treat inflammatory diseases, with its lead candidate Phyto-N in development for conditions including ulcerative colitis, atopic dermatitis, and other indications. The company does not currently have an established distribution schedule. This security may appeal to investors seeking exposure to early-stage pharmaceutical development, though investors should be aware of the risks inherent in developmental stage companies.

CURX performance versus SPY

Price and return data through 2026-10-16.

Total return is 14.9% over the past 1.1 years, 5.0 points behind SPY at 19.9%. Its deepest 1-year drawdown was 95.5%.

CURX key facts

Asset type

Stock

Asset class

Equity

Inception date

08/26/2025

Distribution frequency

None

Last close

$4.62 (as of 2026-10-16)

Market cap

$7,245,273

Average volume

10674.0

Payout ratio

0.0%

EPS

$-7.80

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CURX risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 95.5%.

Who may consider CURX — and who may not

It is a weaker fit for investors who need monthly cash flow (CURX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CURX

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions